anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain new readily drinkable tea, made from a leaf of Zizyphus jujuba Mill. var. inermis Rehd., capable of manifesting suppressing effects on sugar absorption, having a refreshing feeling and providing an extract thereof useful as an ingredient, etc., of a soft drink by heat-treating the raw or dried leaf of Zizyphus jujuba Mill. var. inermis Rehd. CONSTITUTION: This new tea made from a leaf of Zizyphus jujuba Mill. var. inermis Rehd. is obtained by pulverizing the raw or dried leaf of the Zizyphus jujuba Mill. var. inermis Rehd., then, as desired, heating the pulverized leaf with steam at 100 deg.C for 1hr, subsequently heat-treating the resultant leaf at >=120 deg.C temperature for 1-30min and carrying out the roasting. Thereby, the resultant tea is remarkably lowered in bitterness or astringency, sharply reduced in anesthetic actions on taste buds, eliminated from a grassy smell, readily drinkable and capable of manifesting the fragrance, has a refreshing feeling and suppressing effects on sugar absorption and provides its extract suitable as an ingredient, etc., of a soft drink.
Group of adolescents supplemented orally with 6 g / day of pure L-citrulline in capsules. The dose will be met by taking four (3 g) capsules in the morning before the first meal and four capsules (3 g) in the evening after the last meal.
PURPOSE:To compound vitamin C into a solid drug preparation while keeping high stability even under high temperature and humidity condition and in the presence of minerals. CONSTITUTION:Powdery vitamin C is coated with a rubber layer composed of a fluidity-improving agent. The fluidity-improving agent is e.g. silicon dioxide or talc having an average particle diameter of about 0.1-100mum. The rubber layer can be formed with a latex containing the fluidity-improving agent and the latex may be a synthetic latex such as acrylic copolymer, a natural latex or their mixture. An oleaginous substance may be placed between the vitamin C and the rubber layer.
Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks. Participants will provide logs of video segment watching (control).
This is a retrospective cohort study. The sample size of our study includes one hundred case older than 18 years of age and underwent RYGB surgical treatment during the period from 2014 to 2019 and paired severely overweight controls who had no longer gone through bariatric surgery. Patients having BMI (Body Mass Index) much lower than 35 (calculated as the weight (kilograms) / length2 (meters)), a base line diagnosis taken into consideration a medical exclusion for surgical treatment, died in one year of surgical operation and missed statistics at scientific information had been excluded from the study. Data was collected taking in to account each patient history (age, sex, length, weight, BMI, occupation, marital status, and comorbidities) and weight record in every visit from measurements statistics. Outcomes: The primary final results of the study was the weight-change percentage at follow-up in comparison with baseline one. The secondary effects including the clinical events after surgery, micronutrient levels, incidence of diabetes, hypertension, and dyslipidemia.
Participants will receive 140 milligram (mg) of ibrutinib administered as one IMBRUVICA 140-mg oral capsule (Treatment A) in Period 1, 140 mg of ibrutinib administered as one ibrutinib 140-mg oral tablet (Treatment B) in Period 2, then Treatment A in period 3 and then followed by Treatment B in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
PURPOSE:To obtain a plaster capable of stably keeping an ingredient drug component without decomposition, by compounding a plaster composed of a pressure-sensitive adhesive material with a crude drug selected from DAIKAISHI or SUZUKAKENOKI (both are Chinese crude drugs). CONSTITUTION:A plaster composed of a pressure-sensitive adhesive substance such as acrylic adhesive substance or rubbery adhesive substance, etc., is compounded with a crude drug selected from DAIKAISHI (dried fruit or seed of Cola nitida belonging to Cola genus, Sterculiaceae family) and SUZUKAKENOKI (dried bark or leaf of Platanus orientalis belonging to Hamamelidaceae family). The amount of the crude drug is 0.1-20(wt)%, preferably 0.2-5% in the case of powder and 0.01-8%, preferably 0.05-5% in the case of extract. The stabilized plaster is especially effective to a compound containing phenolic hydroxyl group (e.g. salicylic acid derivative) or amine compound (e.g. ethanolamine-type antihistaminic agent) which causes remarkably loss of content in conventional plaster.
Lumbar disc degeneration (LDD) is a prevalent clinical spinal disease characterized by the calcification and degeneration of the cartilage endplate (CEP), which significantly reduces nutrient supply to the intervertebral disc. Traditional Chinese medicine offers a conservative and effective approach for treating LDD. We aimed to investigate the molecular mechanisms underlying the therapeutic effects of Sesamin in LDD treatment. Transcriptome sequencing was used to analyze the effect of Sesamin on LPS-induced ATDC5. We explored the role of BECN2, a target gene of Sesamin, in attenuating LPS-induced degeneration of ATDC5 cells. Our results revealed the identification of 117 differentially expressed genes (DEGs), with 54 up-regulated and 63 down-regulated genes. Notably, Sesamin significantly increased the expression of BECN2 in LPS-induced ATDC5 cell degeneration. Overexpressed BECN2 enhanced cell viability and inhibited cell apoptosis in LPS-induced ATDC5 cells, while BECN2 knockdown reduced cell viability and increased apoptosis. Furthermore, BECN2 played a crucial role in attenuating chondrocyte degeneration by modulating autophagy and inflammation. Specifically, BECN2 suppressed autophagy by reducing the expression of ATG14, VPS34, and GASP1, and alleviated the inflammatory response by decreasing the expression of inflammasome proteins NLRP3, NLRC4, NLRP1, and AIM2. In vivo experiments further supported the beneficial effects of Sesamin in mitigating LDD. This study provides novel insights into the potential molecular mechanism of Sesamin in treating LDD, highlighting its ability to mediate autophagy and inflammation inhibition via targeting the BECN2. This study provides a new therapeutic strategy for the treatment of LDD, as well as a potential molecular target for LDD.
Wheat powdery mildew is one of the most destructive diseases threatening global wheat production. The wild relatives of wheat constitute rich sources of diversity for powdery mildew resistance. Here, we report the map-based cloning of the powdery mildew resistance gene Pm13 from the wild wheat species Aegilops longissima. Pm13 encodes a mixed lineage kinase domain-like (MLKL) protein that contains an N-terminal-domain of MLKL (MLKL_NTD) domain in its N-terminus and a C-terminal serine/threonine kinase (STK) domain. The resistance function of Pm13 is validated by mutagenesis, gene silencing, transgenic assay, and allelic association analyses. The development of introgression lines with significantly reduced chromosome segments of Ae. longissima encompassing Pm13 enables widespread deployment of this gene into wheat cultivars. The cloning of Pm13 may provide valuable insights into the molecular mechanisms underlying Pm13-mediated powdery mildew resistance and highlight the important roles of kinase fusion proteins (KFPs) in wheat immunity.
Patient monitoring system, has a manual scanner to register the drug data for storage in a memory, with an electronic unit to determine adverse effects and contraindications. Patient monitoring system, has a manual scanner to register the drug data for storage in a memory, with an electronic unit to determine adverse effects and contra-indications. For the system to monitor the administration of medications by a patient (1), as each medication is taken for use it is passed manually through a scanner (5) where the machine readable data can be registered. The scanned data are passed to an electronic unit (8) with a memory (6) where the nature of the medication and its time of administration can be accessed. The machine readable data can be a code which is optically scanned, and especially a barcode (4) on the packaging blister, leaflet or package (2). The code can also be an optical, electronic or magnetic code on a code carrier (3) at the medication, as a code chip card.
Lumbar stabilization exercises daily, 10 repetitions each (three times a day) for three months consecutively. All exercises were performed to a count of 7 seconds.
The safety and efficacy of didanosine have not been established in HIV-infected patients with significant underlying liver disease. During combination antiretroviral therapy, patients with preexisting liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities, including severe and potentially fatal hepatic adverse events, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. 

Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV-infected patients treated with hydroxyurea and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. This combination should be avoided [see Adverse Reactions (6 )].
The invention discloses a food for treating diabetes. The food for treating the diabetes comprises the following raw materials in the following proportion: 30-40 grams of chickpeas, 5-10 grams of seabuckthorn fruits, 10-20 grams of Chinese yams, 20-30 grams of mulberry leaves, 20-30 grams of wheat germs, 10-20 grams of oat glucan and 5-10 grams of ginsenoside. The food for treating the diabetes is based on the traditional Chinese medicine principle of concurrent treatment. On basis of traditional therapies for reducing the blood sugar of the patients with the diabetes, a large amount of clinic trials have been performed, so that the food has the functions of improving human body immunity, tonifying the spleen, benefiting the stomach and reducing the blood sugar in the aspect of treating the diabetes. Being taken, the food is capable of effectively controlling blood sugar and urine sugar, as well as ensuring very good restoration of the functions, including energy, physical strength and the like; moreover, the food is capable of stimulating self-repair capacities of the cells, activating islet cell functions and repairing islet B cells. Thus, use of insulin western-drugs to the human body can be gradually stopped, and the functions of the body restore health by taking the food.
Background and Objectives: Endometrial carcinoma is one of the most common gynecological cancers, and benign lesions such as endometrial hyperplasia, polyps, adenomyosis and leiomyomas should be included in the differential diagnosis. Magnetic resonance imaging has an important role in evaluating endometrial cancer and assessing the depth of myometrial invasion, and it closely correlates with the prognosis of the patient. The purpose of this study is to evaluate the MRI semiology of the endometrial carcinomas that mimic benign lesions, the main factors that may affect the correct diagnosis and the feasibility of magnetic resonance imaging to evaluate the depth of the myometrial invasion of endometrial cancer. Materials and Methods: This is a retrospective analysis of 45 patients that underwent MRI examinations and the lesions were pathologically diagnosed as endometrial carcinoma after surgical resection. This study evaluated the staging accuracy of T2-weighted imaging, diffusion-weighted imaging (DWI), ADC mapping and T1-weighted imaging with fat saturation before and after gadolinium injection. Results: In 36 of the 45 cases, the MRI of the lesion showed the characteristics of endometrial cancer and the diagnosis was certain. Nine lesions (20%) were described as unequivocal and had unspecific MR appearance. In eight of the nine cases (89%), the histopathologic report revealed the presence of leiomyomas and two of these cases (22%) were also associated with adenomyosis. The cause of underestimation in these patients was coexisting lesions exhibiting heterogenous intensity and contrast enhancement, which made it difficult to detect the margins of the lesions. The depth of the myometrial invasion was underestimated in nine cases and overestimated in three cases. The staging accuracy with MRI was 74%. There was a significant correlation between MR imaging and histopathologic finding in the assessment of myometrial invasion (p < 0.001). Cervical extension was noted in eight cases (18%), but was missed on MR imaging in two patients and overstaged in none. Six of them were associated with myometrial invasion in more than 50% of the thickness. There was a significant correlation between MR imaging and histopathologic finding in the assessment of cervical extension (p < 0.001). Conclusions: Our data confirm the high accuracy of MRI in the diagnosis and local staging of endometrial carcinoma. The information provided by MRI has an important role in planning the treatment and the prognosis of the patients.
Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
Participants in the control group will not receive any additional treatment, apart from receiving daily emails 15 minutes before the start of their self-reported workout window. This is to control for reminder effects that may be present in the other treatment conditions. Participants in this condition will also receive a lump payment upon completion of an exit survey at the end of the intervention to equalize overall compensation.
BACKGROUND AND AIMS: Hepatitis B virus (HBV)-associated liver cirrhosis (LC), a common condition with high incidence and mortality rates, is often associated with diabetes mellitus (DM). However, the molecular mechanisms underlying impaired glucose regulation during HBV-associated LC remain unclear.
METHODS: Data from 63 patients with LC and 62 patients with LC-associated DM were analysed. Co-culture of NK cells and islet β cell lines were used to study the glucose regulation mechanism. A mouse model of LC was used to verify the effect of S100A8/A9 on the glucose regulation.
RESULTS: Higher levels of interferon (IFN)-γ derived from natural killer (NK) cells and lower levels of insulin emerged in the peripheral blood of patients with both LC and DM compared with those from patients with LC only. IFN-γ derived from NK cells facilitated β cell necroptosis and impaired insulin production. Furthermore, S100A8/A9 elevation in patients with both LC and DM was found to upregulate IFN-γ production in NK cells. Consistently, in the mouse model for LC, mice treated with carbon tetrachloride (CCL4) and S100A8/A9 exhibited increased blood glucose, impaired insulin production, increased IFN-γ, and increased β cells necroptosis compared with those treated with CCL4. Mechanistically, S100A8/A9 activated the p38 MAPK pathway to increase IFN-γ production in NK cells. These effects were diminished after blocking RAGE.
CONCLUSION: Together, the data indicate that IFN-γ produced by NK cells induces β cell necroptosis via the S100A8/A9-RAGE-p38 MAPK axis in patients with LC and DM. Reduced levels of S100A8/A9, NK cells, and IFN-γ could be valuable for the treatment of LC with DM. Accumulation of S100A8/A9 in patients with LC may indicate the emergence of DM.
All patients recruited to the study will receive 3 loading intravitreal injections of Aflibercept (Eylea) at monthly intervals followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow-up will occur when there is evidence of OCT stability in the view of the investigator i.e. there is no further reduction in macular fluid compared to the previous visit. All patients will receive 5 injections before considering them non-responders.
Vitamin B and G concentrates are obtained by plasmolyzing yeast by means of a volatile solvent for vitamins B and G, treating the resulting mass with an alcohol or ester to coagulate the protein and concentrating the liquid product after filtration.  The solid residue on the filter may be used for the preparation of ergosterol.  Fatty acid esters, diethylether, chloroform, diethylenedioxide or acetone may be used as the volatile solvent and methyl or ethyl alcohol or ethylacetate for coagulation of the protein.  The concentrates may be used for increasing the vitamin B and G contents of foods, tonics and drinks, e.g. the concentrates may be mixed with a starch conversion product containing maltose and dextrine, dried malt or wheat germ extract. In an example, ethyl acetate is used for plasmolyzing the yeast and protein is coagulated by means of alcohol.ALSO:The vitamin B and G content of foods is increased by means of a concentrate obtained by plasmolyzing yeast, coagulating protein material by means of alcohols or esters and concentrating the liquid product after filtration.  The concentrates may be added to a starch conversion product containing maltose and dextrine, dried malt or wheat germ extract.
Technologies are provided for assessment of exposure to airborne aerosol pathogens (e.g., SARS-CoV-2). Exposure can be assessed using a model that yields a score quantifying comparative dose which can be classified into an exposure risk category in a particular scenario relative to a high-risk scenario. The model incorporates mechanistic, stochastic, and epidemiological factors that define the particular scenario within an activity region. The model can determine an average concentration of pathogen within the activity region, for a particular exposure duration, using an approach that includes near-field and far-field contributions. In some embodiments, an apparatus can access data from various devices. The data defines at least some of the factors the define the particular scenario. The apparatus can determine an average concentration within the activity region, and can cause a display device to present indicia indicative of the exposure risk.
Sleep disturbances are prevalent in women with HIV (WWH). Tryptophan-kynurenine (T-K) pathway metabolites are associated with alterations in actigraphy derived sleep measures in WWH, although may not always correlate with functional impairment. We investigated the relationship between T-K pathway metabolites and self-reported daytime dysfunction in WWH and women without HIV (WWoH). 141 WWH on stable antiretroviral therapy and 140 demographically similar WWoH enrolled in the IDOze Study had targeted plasma T-K metabolites measured using liquid chromatography-tandem mass spectrometry. We utilized the daytime dysfunction component of the Pittsburgh Sleep Quality Index (PSQI) to assess functional impairment across HIV-serostatus. Lower levels of 5-hydroxytryptophan and serotonin were associated with greater daytime dysfunction in all women. In WWH, daytime dysfunction was associated with increased kynurenic acid (R = 0.26, p < 0.05), and kynurenic acid-tryptophan (KA-T) ratio (R = 0.28, p < 0.01). WWH with daytime dysfunction had a 0.7 log fold increase in kynurenic acid compared to WWH without daytime dysfunction. Kynurenic acid levels and the KA-T ratio were associated with daytime dysfunction in WWH but not in WWoH. Longitudinal studies are needed to establish a causal relationship and directionality between T-K metabolic changes and sleep impairment in WWH.
The present invention provides a compounded non-prescription medication for the treatment of motion sickness. The medication comprises: at least one analgesic selected from the group consisting of acetaminophen, ibuprofen, naproxen and salicylates; at least one histamine H2-receptor antagonist selected from the group consisting of nizatidine, famotidine, cimetidine, ranitidine. famotidine; and at least one antacid selected from the group consisting of calcium carbonate, sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, and bismuth subsalicylate. The medication may optionally comprise at least one additional ingredient selected from the group consisting of spearmint extract and ginger extract. The formulations are consistent in their effectiveness and devoid of the side effects of drowsiness and dry mouth. A presently preferred embodiment of the medication comprises primarily of ibuprofen, famotidine, calcium carbonate, magnesium hydroxide, spearmint extract and ginger extract.
The effect of FABHALTA was evaluated in a multicenter, randomized, double-blind study (APPLAUSE-IgAN, NCT04578834) in adults with biopsy-proven IgAN, eGFR ≥ 20 mL/min/1.73 m2, and urine protein-to-creatinine ratio (UPCR) ≥1 g/g on a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of an SGLT2 inhibitor. Patients with other glomerulopathies or those who had been recently treated with systemic immunosuppressants were excluded. Patients were included in either the Main Study Population (eGFR ≥ 30 mL/min/1.73 m2) or the Severe Renal Impairment population (eGFR ≥ 20 and <30 mL/min/1.73 m2). Within each group, patients were randomized (1:1) to either FABHALTA 200 mg or placebo twice daily. Rescue immunosuppressive treatment could be initiated per investigator discretion during the trial.

Patients were required to be vaccinated against Neisseria meningitidis and Streptococcus pneumoniae and were recommended to be vaccinated against Haemophilus influenzae type b. If the patient had not been previously vaccinated or if a booster was required, vaccination was administered at least 2 weeks prior to first dosing. If FABHALTA treatment was initiated earlier than 2 weeks after vaccination, antibacterial drug prophylaxis was administered.

The efficacy analysis was based on the first 250 patients with an eGFR ≥ 30 mL/min/1.73 m2 (Main Study Population), who had completed or discontinued the study prior to the Month 9 visit. At baseline, the mean age of these patients was 39 years (range 18 to 74 years); 52% were male, 44% White, 54% Asian, and < 1% Black or African American; the mean eGFR was 64 mL/min/1.73 m2; the geometric mean UPCR (sampled from a 24-hr urine collection) was 2.0 g/g, and 12% had a UPCR ≥3.5 g/g. At baseline, 99% of patients were treated with an ACEi or ARB and 13% were on an SGLT2i. Approximately 59% had a history of hypertension, 6% had a history of type 2 diabetes, and 75% had hematuria based on urine dipstick. 

The primary endpoint was the percent reduction in UPCR (sampled from a 24-hr urine collection) at Month 9 relative to baseline (see Table 5). The mean percent change from baseline in UPCR over time is shown in Figure 1.

Figure 1: Geometric Mean Percent Change from Baseline in UPCR by Visit in APPLAUSE-IgAN

Adjusted % change relative to baseline in UPCR were obtained by analyzing the log transformed ratio to baseline in UPCR using an MMRM as described in Table 5. N represents the number of subjects with values non-missing/not imputed as per the intercurrent event handling strategy by visit and treatment group.

Abbreviations: CI, confidence interval; FAB, FABHALTA; MMRM, mixed model repeated measures; N, number of subjects in each group; PBO, placebo; UPCR, urine protein-to-creatinine ratio

The treatment effect on UPCR at Month 9 was consistent across all subgroups including age, sex, race, baseline disease characteristics (such as baseline eGFR and proteinuria levels), and the use of SGLT2i.